Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus dasatinib vs docetaxel plus placebo in castration-resistant prostate cancer
2008-000701-11Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Docetaxel plus dasatinib with Docetaxel plus placebo (2 arms). Primary endpoint: Overall survival. Started Sep 2008; status: completed.
02
Drugs
dasatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-000701-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000701-11.